Fig. 5. CCL20/CCR6 signalling supports angiogenesis in vivo.

a Cross sections of Matrigel plugs removed 21 days after injection into C57BL/6 mice were stained with anti-CD31 antibodies [scale bars represent 100 µm]. Representative pictures and the number of CD31-positive vessels per cross section are shown and represent the mean ± SD of three independent experiments (*P ≤ 0.05; **P≤0.01, Mann–Whitney U test). b Left panels: FpVCT scans showing contrast agent-containing tumour vessels and their distribution and bifurcations in the periphery and within CCL20-expressing B16F10 tumours growing in C57BL/6 wild-type and C57BL/6-CCR6^–/– mice. Representative results are shown. Tumours are indicated by white arrows. Right panels: evaluation of the weight and volume of B16F10 tumours in C57BL/6 wild-type and C57BL/6-CCR6^–/– mice. Tumour weight was measured in grams. The data represent the mean ± SD of twelve independent tumours. Tumour volume was automatically determined by fpVCT datasets and measured in cm³. The data represent the mean ± of eight independent tumours (*P ≤ 0.05, Mann–Whitney U test). c Scheme showing the different bone marrow chimeras generated for tumour experiments. d Analysis of B16F10 tumours in bone marrow chimeras. Tumour weight was measured in grams. Data represent the mean ± SD of seven independent tumours (*P ≤ 0.05, Mann–Whitney U test).